Development of novel platforms for cancer immunotherapy
IVTLab is focused on developing novel platforms for cancer immunotherapy using viruses and cells as starting building blocks.
IVTLab started in 2012 and since then it has produced more than 6 patents, tens of publications (see dedicated section) and has raised more than 4 million euros for research.
One of our patent PeptiCRAD constitutes the core business of a spin-off company that together with the University of Helsinki we have setup. The company name is VALO Therapeutics and the primary mission is to bring PetoCRAD technology to the patients.